vic-1911
Small moleculeexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 28, 2022 (NCT05120570)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
AURKA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06519721 | N/A | Aug 1, 2024 | Jiao Tong University |
| NCT05718882 | N/A | Jul 1, 2023 | Jiao Tong University |
| NCT05374538 | Phase 1 | Sep 30, 2022 | Strategia Therapeutics, Westat, Yale University |
| NCT05489731 | Phase 1 | Aug 30, 2022 | Government of China |
| NCT05120570 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2022 | University of Minnesota |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiao Tong University | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Government of China | Government | 1 | 1 | 1 | 2022 |
| Strategia Therapeutics | For profit | 1 | 1 | 1 | 2022 |
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Westat | For profit | 1 | 0 | 1 | 2022 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2022 |
6 organizations
Page 1 / 1